liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
BETA
Slind Olsen, Renate
Publications (5 of 5) Show all publications
Slind Olsen, R. (2017). Circulating and genetic factors in colorectal cancer: Potential factors for establishing prognosis?. (Doctoral dissertation). Linköping: Linköping University Electronic Press
Open this publication in new window or tab >>Circulating and genetic factors in colorectal cancer: Potential factors for establishing prognosis?
2017 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Colorectal cancer (CRC) is defined as a cancer appearing in the colon or in the rectum. In Sweden, ~ 6300 individuals were diagnosed with the disease in 2014 and ~ 2550 individuals diagnosed with CRC die each year due to their cancer. Surgery is the main treatment option of CRC and a survival rate of ~ 10 % is estimated if distant metastases have developed. It is therefore of importance to find factors that may be useful together with tumour, node, metastasis (TNM) stage to establish early CRC diagnosis, prognosis and follow-up of CRC patients. The aim of this thesis was to study the possible association of CD93, PLA2G4C, PDGF-D and inflammatory cytokines with CRC disease progression.

In a prospective study approach CD93 and PLA2G4C single nucleotide polymorphisms (SNPs) were of potential importance in CRC prognosis.

The T/T genotype of CD93 was associated with an increased CD93 expression in CRC tissue. Further, CRC patients carrying this genotype were associated with disseminated CRC at diagnosis and a lower recurrence-free survival after surgery. The A allele of a SNP of PLA2G4C was a stronger predictor for CRC-specific mortality than the conventional risk factors used in the clinic for selection of TNM stage II patients for adjuvant treatment. This indicates that the T/T genotype of CD93 and the A allele of PLA2G4C may be potential genetic factors related to disease severity and spread. Furthermore, they distinguish CRC patients that may benefit from a more comprehensive follow-up and adjuvant treatment.

To study the putative involvement of PDGF-D in CRC the effects of PDGF-D signalling was studied in vitro. PDGF-D signalling altered the expression of genes of importance in CRC carcinogenesis and proliferation which was blocked by imatinib, a tyrosine kinase inhibitor. This indicates that PDGF-D signalling may be an important pathway in CRC progression and a potential target in CRC treatment.

The analysis of various inflammatory cytokines in plasma at diagnosis showed an association between high levels and increased total- or CRC-specific mortality two years after surgery. High levels of CCL1 and CCL24 was the only cytokines strongly correlated with a worse CRC prognosis after statistical adjustments and may be of interest for further evaluation.

In conclusion, this thesis presents circulating and genetic factors such as CD93, PLA2G4C, PDGF-D, CCL1 and CCL24 that may be of importance in CRC progression and may be of clinical value together with TNM stage in establishing prognosis.

Abstract [sv]

Kolorektal cancer är en tumör i kolon eller rektum. I Sverige diagnosticerades år 2014 ca6300 individer med denna cancertyp och ca 2550 personer dör årligen till följd av kolorektalcancer. Operation är det huvudsakliga behandlingsalternativet för kolorektal cancer och vidfjärrmetastaser är överlevnaden < 10 %. Det är därför viktigt att hitta markörer somtillsammans med TNM-stadium kan ge tidig information om sjukdomens prognos och lämpliguppföljning av patienter.

Utveckling av kolorektal cancer sker genom ackumulering av genetiska mutationer ochepigenetisk nedreglering av tumörsuppressorgener. Därutöver spelar interaktionen mellantumören och dess närmaste omgivning, innehållande tillväxt- och inflammatoriska faktorer,en viktig roll i tumörens utveckling och metastasering.

Syftet med avhandlingen var att studera associationen mellan CD93, PLA2G4C, PDGF-D samtinflammatoriska cytokiner och kolorektal cancer progression.

En prospektiv studie visade att CD93 och PLA2G4C SNP var potentiellt viktiga förbedömningav kolorektal cancer prognos. T/T genotypen av SNP rs2749817 i CD93 var associerad medhögre uttryck av CD93 i kolorektal cancer vävnad, främst bland patienter i stadium IV.Därutöver observerades fler återfall efter operation hos patienter med T/T genotypen. Aallelen hos PLA2G4C SNP rs1549637 är en möjligtvis bättre markör för cancerspecifiköverlevnad vid stadium II än faktorer som idag används för att selektera patienter tilladjuvant behandling. Sammantaget antyder detta att T/T genotypen av CD93 och A allelenav PLA2G4C kan vara genetiska markörer relaterade till allvarlig tumörsjukdom ochspridning. Därutöver kan de eventuellt selektera patienter som kräver tätare uppföljning ochadjuvant behandling.

För att studera den förmodade inblandningen av PDGF-D i kolorektal cancer undersöktesdess effekt på PDGF-D signalering in vitro. PDGF-D signaleringen förändradegenexpressionen av gener involverade i tumörutveckling och spridning, vilken kundeblockeras av tyrosinkinashämmaren imatinib. Det antyder att PDGF-D signalering kan vara enviktig faktor vid kolorektal cancer progression och ett potentiellt mål för behandling. Analysen av ett flertal inflammatoriska cytokiner visade en korrelation mellan högacytokinnivåer och ökad cancerspecifik och total dödlighet två år efter operation. Höga CCL1och CCL24 nivåer var de enda faktorerna som förblev signifikant associerade medcancerspecifik mortalitet vid fördjupad statistisk analys och bör studeras vidare.

Sammanfattningsvis presenterar denna avhandling cirkulerande och genetiska faktorersåsom CD93, PLA2G4C, PDGF-D, CCL1 and CCL24 som eventuellt är viktiga vid bedömning avkolorektal cancer progression tillsammans med TNM stadium.

Place, publisher, year, edition, pages
Linköping: Linköping University Electronic Press, 2017. p. 77
Series
Linköping University Medical Dissertations, ISSN 0345-0082 ; 1568
National Category
Cancer and Oncology Gastroenterology and Hepatology Urology and Nephrology Surgery Hematology
Identifiers
urn:nbn:se:liu:diva-136841 (URN)10.3384/diss.diva-136841 (DOI)9789176855553 (ISBN)
Public defence
2017-06-05, Originalet, Qulturum, Länssjukhuset Ryhov, Jönköping, 09:00 (Swedish)
Opponent
Supervisors
Available from: 2017-04-28 Created: 2017-04-28 Last updated: 2017-05-11Bibliographically approved
Gacic, J., Vorkapic, E., Slind Olsen, R., Söderberg, D., Gustafsson, T., Geffers, R., . . . Wågsäter, D. (2016). Imatinib reduces cholesterol uptake and matrix metalloproteinase activity in human THP-1 macrophages. Pharmacological Reports, 68(1), 1-6
Open this publication in new window or tab >>Imatinib reduces cholesterol uptake and matrix metalloproteinase activity in human THP-1 macrophages
Show others...
2016 (English)In: Pharmacological Reports, ISSN 1734-1140, E-ISSN 2299-5684, Vol. 68, no 1, p. 1-6Article in journal (Refereed) Published
Abstract [en]

Background: Imatinib mesylate (Glivec, formerly STI-571) is a selective tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. However, there are reports suggesting that imatinib could be atheroprotective by lowering plasma low-density lipoprotein (LDL). Aim: To investigate the potential inhibitory effect of imatinib on cholesterol uptake in human macrophages as well as its effect on matrix metalloproteinase (MMP) activity. Methods and results: Uptake of fluorescence-labeled LDL was analyzed using flow cytometry. Macrophages treated with imatinib showed a 23.5%, 27%, and 15% decrease in uptake of native LDL (p &lt; 0.05), acetylated LDL (p &lt; 0.01), and copper-modified oxidized LDL (p &lt; 0.01), respectively. Gel based zymography showed that secretion and activity of MMP-2 and MMP-9 were inhibited by imatinib. Using GeneChip Whole Transcript Expression array analysis, no obvious gene candidates involved in the mechanisms of cholesterol metabolism or MMP regulation were found to be affected by imatinib. Instead, we found that imatinib up-regulated microRNA 155 (miR155) by 43.8% and down-regulated ADAM metallopeptidase domain 28 (ADAM28) by 41.4%. Both genes could potentially play an atheroprotective role and would be interesting targets in future studies. Conclusion: Our results indicate that imatinib causes post-translational inhibition with respect to cholesterol uptake and regulation of MMP-2 and MMP-9. More research is needed to further evaluate the role of imatinib in the regulation of other genes and processes. (c) 2015 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Sp. z o.o. All rights reserved.

Place, publisher, year, edition, pages
POLISH ACAD SCIENCES INST PHARMACOLOGY, 2016
Keywords
Atherosclerosis; Cholesterol; Imatinib; Macrophages
National Category
Biochemistry and Molecular Biology
Identifiers
urn:nbn:se:liu:diva-125158 (URN)10.1016/j.pharep.2015.05.024 (DOI)000368567800001 ()26721343 (PubMedID)
Note

Funding Agencies|Swedish Research Council [K2013-99X-22231-01-5]

Available from: 2016-02-15 Created: 2016-02-15 Last updated: 2018-07-18
Slind Olsen, R., Andersson, R. E., Zar, N., Löfgren, S., Wågsäter, D., Matussek, A. & Dimberg, J. (2016). Prognostic significance of PLA2G4C gene polymorphism in patients with stage II colorectal cancer.. Acta Oncologica, 55(4), 474-479
Open this publication in new window or tab >>Prognostic significance of PLA2G4C gene polymorphism in patients with stage II colorectal cancer.
Show others...
2016 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 55, no 4, p. 474-479Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Phospholipase A2 Group IV C (PLA2G4C) catalyzes the release of certain fatty acids from phospholipids and plays a role in a range of physiological functions, such as remodeling of cell membranes and the production of prostaglandins. Furthermore, it has been proposed that PLA2G4C plays an important role in breast cancer cell chemotaxis. This study aimed to investigate the effect of a single nucleotide polymorphism (SNP) rs1549637 (T>A) of the PLA2G4C gene on the prognosis of colorectal cancer (CRC).

MATERIAL AND METHODS: Whole blood DNA was extracted from 381 patients with CRC and 618 controls, and a TaqMan SNP genotyping assay was used to determine the distribution of the genotypes. Cancer-specific and disease-free survival was analyzed by Kaplan-Meier graphs and by uni- and multivariable Cox regression.

RESULTS: The cancer-specific survival differed between the genotypes (p = 0.019) and the carriers of the A allele were associated with the highest risk of CRC death, with a hazard ratio (HR) of 1.72 [95% confidence interval (CI) 1.17-2.53, p = 0.006] compared with homozygous carriers of the T allele. This increased mortality in the carriers with the allele A was especially marked in stage II with an HR of 3.84 (95% CI 1.51-9.78, p = 0.005).

CONCLUSION: The A allele in PLA2G4C SNP (rs1549637) is associated with a worse prognosis in patients with CRC, especially in stage II disease, and it could be a potential prognostic biomarker in the planning of individual adjuvant therapy in stage II patients.

Place, publisher, year, edition, pages
Taylor & Francis Group, 2016
National Category
Cancer and Oncology Cell and Molecular Biology
Identifiers
urn:nbn:se:liu:diva-125986 (URN)10.3109/0284186X.2015.1073350 (DOI)000372125400012 ()26364726 (PubMedID)
Note

Funding agencies: Futurum; Academy of Healthcare; Region Jonkoping County, Sweden; Foundation of Clinical Cancer Research, Jonkoping Sweden; University College of Health Sciences, Jonkoping, Sweden

Available from: 2016-03-10 Created: 2016-03-10 Last updated: 2018-01-10
Slind Olsen, R., Lindh, M., Vorkapic, E., Andersson, R. E., Zar, N., Lofgren, S., . . . Wågsäter, D. (2015). CD93 gene polymorphism is associated with disseminated colorectal cancer. International Journal of Colorectal Disease, 30(7), 883-890
Open this publication in new window or tab >>CD93 gene polymorphism is associated with disseminated colorectal cancer
Show others...
2015 (English)In: International Journal of Colorectal Disease, ISSN 0179-1958, E-ISSN 1432-1262, Vol. 30, no 7, p. 883-890Article in journal (Refereed) Published
Abstract [en]

Cluster of differentiation 93 (CD93) is involved in apoptosis and inflammation and has a suggested role in angiogenesis, and all of which are involved in the development and dissemination of cancer. We evaluated the expression of CD93 and the association with two single nucleotide polymorphisms (SNPs), rs2749812 and rs2749817, as possible biomarkers in colorectal cancer (CRC). Tissue levels and plasma levels of CD93 were measured using an enzyme-linked immunosorbent assay (ELISA). Expression of CD93 was determined by immunohistochemistry, western blot and gene expression analysis. Genotype frequencies were established for the SNPs by real-time polymerase chain reaction (PCR), and the association with tumour stage and survival was analysed. Total CD93 levels were 82 % higher (P less than 0.001) in tumours compared to matched normal tissues. Mean levels of soluble CD93 in plasma were 30 % lower (P less than 0.001) in the patients compared to the controls. The T/T genotype of SNP rs2749817 was more common in stage IV patients, with consequently higher risk of CRC death (T/T vs. C/C and C/T; hazard ratio (HR) = 1.73, 95 % confidence interval (CI) = 1.11-2.67, P = 0.014), and was associated with a higher risk of CRC recurrence after radical operation (T/T vs. C/C and C/T; HR = 2.07, CI = 1.22-3.51, P = 0.007). We showed that the T/T genotype of SNP rs2749817 is associated with disseminated cancer at diagnosis and an increased recurrence rate after radical operation. Patients with this genotype may benefit from early identification.

Place, publisher, year, edition, pages
Springer Verlag (Germany), 2015
Keywords
Biomarker; Colorectal cancer; Genotype; Prognosis; Single nucleotide polymorphism; Survival
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-120141 (URN)10.1007/s00384-015-2247-1 (DOI)000356350900003 ()26008729 (PubMedID)
Note

Funding Agencies|Foundation of Clinical Cancer Research, Jonkoping [110426-1]; Futurum; Academy of Healthcare; County Council of Jonkoping [FUTURUM-105891]; FORSS, the Research Council of Southeastern Sweden [FORSS-373251]

Available from: 2015-07-14 Created: 2015-07-13 Last updated: 2017-12-04
Dimberg, J., Slind Olsen, R., Skarstedt, M., Lofgren, S., Zar, N. & Matussek, A. (2014). Polymorphism of the p38 beta gene in patients with colorectal cancer. Oncology Letters, 8(3), 1093-1095
Open this publication in new window or tab >>Polymorphism of the p38 beta gene in patients with colorectal cancer
Show others...
2014 (English)In: Oncology Letters, ISSN 1792-1074, E-ISSN 1792-1082, Vol. 8, no 3, p. 1093-1095Article in journal (Refereed) Published
Abstract [en]

The p38 mitogen-activated protein kinase (MAPK) signaling pathways have been proposed to participate in the pathological process of cancer by affecting inflammation, proliferation, metastasis and cell survival. A single nucleotide polymorphism (SNP; rs2235356, -1628A -greater than G) in the promoter region of the p38 beta gene has been proposed as a genetic modifier for colorectal cancer (CRC) in a Chinese population. The present study evaluated the susceptibility of patients possessing this SNP to CRC, in addition to determining its association with clinical parameters in Swedish patients with CRC. Using the LightSNiP genotyping assay, this SNP was screened in 389 patients with CRC and 517 control subjects. No significant difference in the genotype distribution or in the allelic frequencies was identified between the two groups nor was any association identified with the clinical parameters. These findings indicate that the -1628A -greater than G polymorphism of the p38 beta gene is not significantly associated with a susceptibility to CRC in a Swedish population.

Place, publisher, year, edition, pages
Spandidos Publications, 2014
Keywords
p38 beta; promoter region; single nucleotide polymorphism; colorectal cancer
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-110697 (URN)10.3892/ol.2014.2315 (DOI)000340854600024 ()25120664 (PubMedID)
Note

Funding Agencies|Futurum; Academy for Healthcare; County Council (Jonkoping, Sweden) [105891]; Foundation of Clinical Cancer Research (Jonkoping, Sweden) [110426-1]; University College of Health Sciences (Jonkoping, Sweden)

Available from: 2014-09-23 Created: 2014-09-19 Last updated: 2017-12-05
Organisations

Search in DiVA

Show all publications